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Junctional adhesion molecules (JAMs) play a critical role in cell permeability, polarity and migration. JAM-A, a key protein of the JAM
family, is altered in a number of conditions including cancer; however, consequences of JAM-A dysregulation on carcinogenesis
appear to be tissue dependent and organ dependent with significant implications for the use of JAM-A as a biomarker or
therapeutic target. Here, we test the expression and prognostic role of JAM-A downregulation in primary and metastatic colorectal
cancer (CRC) (n= 947). We show that JAM-A downregulation is observed in ~60% of CRC and correlates with poor outcome in four
cohorts of stages II and III CRC (n= 1098). Using JAM-A knockdown, re-expression and rescue experiments in cell line monolayers,
3D spheroids, patient-derived organoids and xenotransplants, we demonstrate that JAM-A silencing promotes proliferation and
migration in 2D and 3D cell models and increases tumour volume and metastases in vivo. Using gene-expression and proteomic
analyses, we show that JAM-A downregulation results in the activation of ERK, AKT and ROCK pathways and leads to decreased
bone morphogenetic protein 7 expression. We identify MIR21 upregulation as the cause of JAM-A downregulation and show that
JAM-A rescue mitigates the effects of MIR21 overexpression on cancer phenotype. Our results identify a novel molecular loop
involving MIR21 dysregulation, JAM-A silencing and activation of multiple oncogenic pathways in promoting invasiveness and
metastasis in CRC.
Cell Death & Differentiation; https://doi.org/10.1038/s41418-021-00820-0
INTRODUCTION
Junctional adhesion molecule A (JAM-A) is a critical component for
the maintenance of epithelial cell homoeostasis and preservation
of barrier function in the large intestine. In physiological
conditions, JAM-A regulates paracellular permeability and controls
ionic and water flux protecting against pathogens. Aberrant JAM-
A expression has been linked to enhanced colon epithelial
permeability, increased inflammation due to leucocyte transmi-
gration and loss of barrier function in pre-clinical models and
patients with inflammatory bowel disease [1].
Analyses of JAM-A expression and function in different cancer types
including breast [2–4], lung [5] and nasopharyngeal cancers [6], as well
as in haematological malignancies [7], have produced conflicting
results, suggesting that JAM-A expression and its role in carcinogenesis
might be either tissue/organ specific or stage dependent.
In gastrointestinal tumours, loss of JAM-A has been reported as
a negative prognosticator in patients with pancreatic [8] and
gastric cancers [9]. Pre-clinical data suggest that Apc loss induces
JAM-A downregulation in the intestine of genetically engineered
mouse models (GEMMs) eliciting loss of barrier function, loss of
polarity and inflammation [10]. No data are currently available on
JAM-A expression in early and metastatic colorectal cancer (CRC).
Here, we tested prognostic and functional implications of JAM-A
dysregulation, in early and metastatic CRC.
MATERIALS AND METHODS
Patients’ TMAs cohorts
The Glasgow Royal Infirmary TMA Cohort (Glasgow, UK) included 266
evaluable core cases composed of 247 stages I–III sporadic CRC and 19
healthy control tissues. The Basel University Hospital Cohort TMA (Basel,
Received: 13 October 2020 Revised: 7 June 2021 Accepted: 9 June 2021
1Division of Molecular Pathology, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK. 2Department of Cancer Biology and Genetics, Comprehensive
Cancer Center, The Ohio State University College of Medicine, Columbus, OH, USA. 3School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing,
University of Newcastle, Newcastle, NSW, Australia. 4Hunter Medical Research Institute, New Lambton Heights, NSW, Australia. 5Bioinformatics Core Unit, Institute of Oncology
Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Bellinzona, Switzerland. 6Swiss Institute of Bioinformatics, Bellinzona, Switzerland. 7Cancer
Research UK Beatson Institute, Glasgow, UK. 8Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. 9Department of Biomedical Sciences, Humanitas University, Milan,
Italy. 10IRCCS Humanitas Research Hospital, Milan, Italy. 11Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK. 12Department of Medicine, Surgical
Pathology Unit, University of Padua, Padua, Italy. 13Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy. 14Department of Medicine, The Royal
Marsden Hospital, London, UK. 15Division of Surgery and Cancer, Imperial College London, London, UK. ✉email: nicola.valeri@icr.ac.uk
Edited by G. Melino
www.nature.com/cdd
Official journal of CDDpress
Switzerland) included 659 evaluable core cases composed of 644 stages
II–III sporadic CRC and 15 healthy control tissues. All patients gave
informed consent. Commercial TMA Cohort (CO702a and HLin-Ade075Met-
01; US Biomax Inc, Rockville, USA) included a total of 127 evaluable core
cases of which 56 were evaluable primary CRC (stages I–IV, CO702a and
grades 1–3, HLin-Ade075Met-01), 15 were healthy control tissues and 56
were evaluable CRC metastasis tissues at different sites. Membranous and
cytoplasmic JAM-A were measured using the histo-score (H-score) to
assess the intensity of immunoreactivity as per the following formula: (3 ×
percentage of strong staining)+ (2 × percentage of moderate staining)+
(1 × percentage of weak staining), resulting in a range between 0 and 300.
Cell lines and patient-derived organoids (PDOs)
CRC cell lines were purchased from ATCC. DLD-1 MIR21wt and MIR21KO
were a kind gift from Jian Yu (University of Pittsburgh Cancer Institute,
Pittsburgh, USA) to CMC (Ohio State University Columbus, USA) and RKO
MIR21wt and MIR21KO were purchased from Horizon Discovery (Cambridge,
UK) and were cultured in McCoy’s 5A or DMEM modified medium,
respectively, (Gibco, Carlsbad, CA, USA) under standard conditions at 37 °C
with 5% of CO2 in a controlled incubator. All cell lines were supplemented
with 10% FBS (Gibco) plus 1% penicillin/streptomycin mixture (Gibco).
Human organoids derived from tumour biopsies of metastatic CRC patients
were previously described [11]. All cell models were regularly tested for
mycoplasma contamination.
Plasmids and lentiviral infections
TRIPZ lentiviral plasmids for JAM-A silencing (TRIPZ JAM-A sh) and relative
control (TRIPZ JAM-A CTRL) were purchased from Thermo Fisher Scientific
(Waltham, MA, USA). Lentiviral particles production and target cells transduc-
tion was performed as per the manufacturer’s instructions. MIR21-
overexpressing vector generation and cell transduction was previously
described [12]. Following viral transductions infected cells were selected with
puromycin (10μg/ml Caco-2 and 2 μg/ml DLD-1, 1 μg/ml PDOs) for 2 weeks.
Minicircle (MC) plasmids
MC plasmids (System Biosciences, Palo Alto, CA, USA) were generated as
per the manufacturer’s instructions. Fragments obtained by in-fusion
cloning were used in order to generate MC-JAM-A CDS WT 3′-UTR and MC-
JAM-A CDS Δ21 3′-UTR. Amplicons containing fusion products were PCR
amplified by means of Phusion high fidelity PCR kit and digested with NheI
and SwaI (New England Biolabs).
Transient transfections
All transfections were performed using Lipofectamine 2000 (Thermo Fisher
Scientific) with 50 nM Precursor-miR for MIR21 or negative control
precursor (Thermo Fisher Scientific). For silencing experiments, SiRNA
pools ON-TARGETplus for JAM-A and relative negative controls, miRCURY
LNA™ anti-MIR21 or negative control miRCURY knockdown probes (Exiqon,
Vedbaek, Denmark) were used at 50 nM. Forty-eight hours post transfec-
tion cells were harvested for analyses.
Nanostring nCounter
nCounter Nanostring (NanoString, Seattle, WA, USA) was used for
expression analysis of 770 cancer-related genes with human PanCancer
panel (cat GXA-PATH1-12) following the manufacturer’s protocol and
conditions. Raw data were log-transformed and normalised by the
quantile method after application of a correction factor. Data were
filtered to exclude features below the detection threshold in at least
half of the samples. p values were used to rank RNAs of interest
and correction for multiple comparisons was done by the
Benjamini–Hochberg method [13].
Migration assay
Migration assays were performed as previously described [14] in 0.1% of
gelatine (Sigma-Aldrich) coated plates. Migration of cells from spheroid to
gelatine was monitored at days time points with Celigo®. Analysis was
performed on ten replicates for each experiment and in three independent
experiments. Area was calculated and difference in migration was
calculated as percentage with following formula: (A1− A0)/A1 × 100 where
A1 is the calculated area at time point 1 and A0 is the area calculated at
time 0 (time point of spheroid transfer) for each sample.
Protein arrays
Global protein expression following JAM-A silencing was performed by
means of 660 Human Array (RayBiotech). Six hundred micrograms of total
protein extract as previously described [15] was outsourced to RayBiotech.
Protein arrays and quantification analysis was performed by RayBiotech as
standard company procedure.
Proteins’ phosphorylation status was assessed by mean of R&D Proteome
Profiler kit (Bio-Techne, R&D Systems) and Luminex assay (Milliplex, Millipore)
as per the manufacturer’s instructions using 600 and 20 µg of total protein,
respectively. Data acquisition and quantification analysis were performed by
LicoR software for R&D protein array and by Luminex 100 software and Excel
spreadsheet for Luminex assay.
Luciferase assay
JAM-A partial 3′-untranslated region (3′-UTR) was PCR amplified—transcript
position 2944-3179 on NM_016946.4—encompassing MIR21 predicted bind-
ing site (https://bibiserv2.cebitec.uni-bielefeld.de/rnahybrid [16], and cloned
downstream of firefly luciferase gene in the pGL3 modified vector (Promega,
Madison, WI, USA) between restriction sites SpeI and SacII. A deletion by site
direct mutagenesis kit (Agilent, Santa Clara, USA) was generated (pGL3-JAM-A-
3′UTR-Δ21) as per the manufacturer’s instructions. Cells were transfected with
1 µg of pGL3-JAM-A-3′UTR wild-type or pGL3-JAM-A-3′UTR-Δ21 firefly
luciferase reporter vector, 0.1 µg of phRL-SV40 renilla control vector (Promega).
Firefly and renilla luciferases activities were measured 48 h post transfection by
Dual-Luciferase® Reporter DLR™ assay (Promega). Each firefly luciferase
emission was normalised to that of renilla for each sample well. Every reaction
was performed in triplicate and in three independent experiments.
In-fusion cloning
Fusion transcripts were generated with In-Fusion® HD Cloning Kit (Takara Bio,
Kusatsu, Japan) between JAM-A coding sequence (CCDS1213.1) and its
partial 3′UTR or with the 3′UTR with the MIR21 deleted binding site obtained
by direct mutagenesis with QuikChange II (Agilent). Transcripts were cloned
into pBABE vector with BamHI and SalI (New England Biolabs).
Retroviral transduction
Retroviral infection of the RKO cell line was achieved by using pBABE-JAM-
A CDS WT 3′-UTR. Phoenix-ampho cells were used as packaging cells for
retroviral production. After viral infection puromycin (6 µg/ml) was added
to the medium for clonal selection for 1 week.
Immunohistochemistry (IHC)
IHC on TMAs and mice tissues were performed as follows: slides were
deparaffinised and rehydrated. Heat-mediated antigen retrieval was
performed in sodium citrate buffer (10 mM; 0.05% Tween-20; pH= 6.0)
for 25min at 110 °C. A 3% peroxidase solution was added followed by
DAKO blocking reagent for 1 h. Primary antibodies (Online Appendix:
Reagents) were applied in DAKO antibody dilution buffer for 1 h at room
temperature. Detection was performed with DAKO Envision+ kit (DAKO,
Cambridgeshire, UK). Positive and negative controls slides were included in
every staining procedure.
Western blot
Immunoblotting was performed as previously described [12]. Membranes
were incubated with primary antibodies (Online Appendix: Reagents),
overnight at 4 °C. Then, with relative secondary HRP-conjugated polyclonal
goat anti-rabbit or goat anti-mouse antibody (Cell Signalling, Danvers,
USA) for 1 h. ECL prime kit (Amersham Biosciences, Chalfont, UK) was used
to develop the signal. Standard film and Odyssey Li-COR machine were
employed to acquire band images.
Rap2c activation
RAP2c activation status was assessed with RAP2c kit (Cell Biolabs, CA, USA)
as per the manufacturer’s instructions
Immunofluorescence
Immunofluorescence was performed on cells grown in coverslips and snap
frozen embedded PDOs. Cells were fixed with 4% formaldehyde then
incubated with blocking buffer solution (5% BSA in PBS) for 1 h. Primary
antibodies (Online Appendix: Reagents) were applied in antibody dilution
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buffer (1% BSA in PBS) for 1 h at room temperature. Secondary antibody
Alexa Fluor 488 (Thermo Fisher Scientific) was applied for 1 h. Hoechst
33342 (Sigma-Aldrich, St. Louis, MO) was used for nuclei counterstaining.
Vectashield antifade mounting medium (VWR, Leicestershire, UK) was
added for reduction of photobleaching. Pictures were acquired with
confocal microscope Zeiss-LSM700 at 40× magnification and Zeiss
2009 software (Carl Zeiss, Jena, Germany).
In situ hybridisation
ISH was performed as we previously described [12, 15].
DNA extraction, bisulfite sequencing and MS PCR
DNA from cell lines was extracted with Qiagen DNA mini kit (Qiagen,
Hilden, Germany) as per the manufacturer’s instructions. DNA was
subjected to sodium bisulfite treatment with EZ DNA Methylation Gold
kit (ZYMO Research, Irvine, CA, USA). Positive universal methylated DNA
and negative un-methylated DNA controls (EpiTect PCR control DNA set;
Qiagen) were included in each assay in order to monitor sodium bisulfite
conversion efficiency. Converted DNA (20 ng) was used for methylation-
specific PCR and bisulfite sequencing.
Bisulfite sequencing
The region upstream (chr1: 161020929-161021435) of JAM-A genomic
position containing a CpG island with predicted 41 CpGs was amplified by
PCR. Four microliters of PCR template were subjected to TOPO® TA cloning
as per the manufacturer’s instructions (Thermo Fisher Scientific). Five
representative clones were sequenced by direct Sanger Sequencing (MRC
PPU DNA Sequencing and Service, Dundee, UK).
5-Aza-2′-deoxycytidine treatment
5-Aza-2′-deoxycytidine (Sigma-Aldrich) was added to cells’ growth medium
at a final concentration of 10 μM. As a control, cells treated with DMSO
were included. Medium was replaced every day with addition of 5-Aza-2′-
deoxycytidine. After 3 days of treatment, cells were recovered for
subsequent DNA and RNA analyses.
Total RNA extraction
Total RNA from cell lines was isolated using TRIZOL method (Invitrogen,
Carlsbad, CA, USA). RNA quantity and quality were assessed with
Nanodrop2000 spectrophotometer (Thermo Fisher Scientific). Only RNA
with an absorbance read ratio 260/280 between 1.8 and 2.0 was used for
experiments.
RT-qPCR
Total RNA was reverse transcribed with microRNA Reverse Transcription Kit
(Thermo Fisher Scientific) and expression analysed with TaqMan® assay and
probes for hsa-miR-21-5p (Thermo Fisher Scientific) and RNU48 as per the
manufacturer’s instructions. For gene expression, High-Capacity RNA-to-cDNA™
Kit (Thermo Fisher Scientific) and SYBR™ Green qPCR with SYBR™ Select Master
Mix (Thermo Fisher Scientific) were used. Specific primers were designed for
each gene transcript by Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/) and are
listed in Online Appendix: Reagents. All reactions, including no-template
controls, were run in Bio-Rad C-1000 touch thermocycler (Bio-Rad, Hercules,
CA, USA) and Applied Biosystems® StepOnePlus™ Real-Time PCR system
(Thermo Fisher Scientific). Each sample was tested in triplicate. Analysis of data
was performed with SDS 2.4.1 software (Thermo Fisher Scientific). Relative
changes in expression were evaluated by using the 2ΔCt formula.
Scratch wound assay
Cells were seeded at 3000 cells/well and allowed to reach complete
confluence. Following scratch, medium containing doxycycline was replaced
and images captured at different days time point with Evos-FL microscope
(Thermo Fisher Scientific) or Incucyte S3 (Essen Bioscience, Hertfordshire, UK)
until wound closure. Migration capacity was calculated as percentage of
wound closure with the following formula: (D0−D1)/D0 × 100 where D1 is the
calculated margin distance at time point 1 and D0 is the margin distance
calculated at time 0 for each sample.
Growth assays
Growth assays were performed as previously described [14] with 1000
cells/well and Celigo® (Nexcelom Bioscience, Lawrence, MA, USA)
cytometer. Scans were repeated at time points and medium with
doxycycline was replaced every 48 h. Analysis was performed on 12
replicates for each experiment and in three independent experiments.
Spheroids growth was calculated by the average differences in spheroids
volumes at time points obtained in μm3: V= 4/3 π r3. Pictures for each well
were exported in ImageJ software [17] for analysis.
Soft agar
Cells (20,000 cells/well) in three replicates were seeded with 20% FBS following
mixing and an equal volume of 0.8% agarose (Sigma-Aldrich) solution. The
mixture was then poured onto a bed of 1.4% agarose in PBS (FMC BioProducts,
Philadelphia, PA, USA). At different time point, pictures were captured with
EVOS-FL microscope with phase contrast and RFP channels (Thermo Fisher
Scientific). Colonies were then stained and fixed with 0.005% crystal violet
(Sigma-Aldrich) and 4% formaldehyde for 1 h.
Tumour xenograft models
All in vivo experiments were performed in accordance with UK Home Office
regulations under the Animals Scientific Procedures Act 1986 and in
accordance with UK National Cancer Research Institute guidelines and the
ARRIVE guidelines [18]. CRC xenograft tumours were established subcuta-
neously in 6-7–week-old female nu/nu mice (Charles River, Wilmington, USA)
with 2 × 106 cells of Caco-2 TRIPZ CTRL and JAM-A sh in serum-free medium
(Gibco) injected in a single flank. CRC xenograft metastatic sites were
established intravenously through tail vein in 6–7-week-old female nu/nu mice
(Charles River) with 1 × 106 DLD-1 TRIPZ CTRL and JAM-A sh in serum-free
medium (Gibco). CRC PDO xenograft tumours were established subcuta-
neously in 6–7-week-old female NOD-scid IL2Rgnull mice (Charles River) with
1 × 106 cells PDO-TRIPZ-MIR21 and PDO-TRIPZ CTRL cells injected embedded
in 100% Matrigel (BD Biosciences) in a single flank. Animals were housed in
specific pathogen-free rooms in autoclaved, aseptic microisolator cages with a
maximum of five animals per cage. At 9 and 12 weeks post inoculation, mice
were culled and primary tumours and lungs removed for paraffin embedding.
Statistical methods
Survival was calculated from the date of diagnosis to date of death from
any cause for overall survival, to the date of CRC-specific death for disease-
specific survival and to the date of relapse for relapse-free survival.
Differences in survival between patients with low expression and high
JAM-A expression were calculated using the Kaplan–Meier method and
compared using the log-rank test. For the GSE40966, GSE14333 and TCGA
cohorts a survival cut-off was established based on statistical testing. An
algorithm separated the samples of a dataset into two groups based on
the gene expression.
RESULTS
Deregulated JAM-A expression and localisation is a common
feature of human CRC
JAM-A protein expression was tested by IHC in three independent
cohorts of primary and metastatic CRC tissue (Supplementary Fig. S1).
In the first series [UK cohort (n= 247)], JAM-A staining showed patchy
cytoplasmic localisation or complete loss in more than 50% of primary
CRC cases. Membranous staining and no cytoplasmic signal were
observed in 95% of paired normal tissues and only in 42.1% of CRC
cases (Fig. 1A). Similar findings were observed in a second
independent set [Swiss cohort (n= 644)], with 64% of primary CRC
cases showing negative or patchy JAM-A staining, while 100% of
matched normal controls exhibiting exclusively membranous staining
(Fig. 1A). In the third series [Biomax cohort (n= 56)], we tested JAM-A
deregulation in the progression from normal to metastatic CRC. JAM-
A staining was negative in 7.1% of primary tumours and in 14.3% of
paired metastases, while a patchy cytoplasmic expression pattern was
observed in 48.2% of primary tumours and in 44.6% of paired
metastases (Fig. 1B). Overall, JAM-A expression appeared reduced,
scattered across the cytoplasm or completely lost in more than 50%
of all cases, both in primary CRC and metastatic deposits (Fig. 1B, C).
Supporting these observations, immunofluorescence analysis of ten
PDOs from liver, nodal and pelvic metastases of heavily pre-treated
gastrointestinal cancer patients [11] showed JAM-A loss in 70% of
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Fig. 1 JAM-A expression in colorectal cancer. A JAM-A expression and sub-cellular localisation in cancer and normal tissues in the UK (n=
266; normal= 19, cancer= 247) and Swiss (n= 659; normal= 15, cancer= 644) cohorts; data are shown as percentage. B JAM-A expression
and sub-cellular localisation in paired normal colon tissue, primary cancer and metastasis, in the Biomax cohort (n= 127; normal= 15,
cancer= 56; metastasis= 56). C Representative images showing patterns of JAM-A expression in normal colon tissue, primary
adenocarcinoma and liver metastasis; two representative cases showing JAM-A expression in matched normal tissues (left). Both lesions
showed a strong membranous and a moderate cytoplasmic staining. Upper case showed a faint/moderate membranous and a weak
cytoplasmic staining (centre top), whereas the liver metastasis was characterised by a faint membranous and a moderate/strong cytoplasmic
staining (right top). Lower case showed JAM-A expression loss in both primary and metastatic samples (centre and right bottom). Scale bars
100 μm. D JAM-A expression by immunofluorescence staining in PDOs derived from cancer patients. Representative images of low and high
expression cases, scale bars 20 μm. Box and whisker plots representing H-scores for JAM-A membranous and cytoplasmic staining in normal
colon vs cancer in the UK (E), Swiss (F) [Mann–Whitney test] cohorts and Biomax (G) [Kruskal–Wallis test] cohort. Overall survival Kaplan–Meier
curves in stages II–III (H) and stage II only (I) CRC patients in the Swiss cohort, according to JAM-A expression.
A. Lampis et al.
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cases (Fig. 1D and Supplementary Fig. S2A). H-score for JAM-A
membranous staining was consistently reduced in all three cohorts
when primary cancer and metastases were compared to normal
tissue (p< 0.001) (Fig. 1E–G). Furthermore, a stage dependent effect
was observed in localised CRC cases where, membranous JAM-A
staining appeared significantly reduced in stage III compared to stage
II tumours (Supplementary Fig. S2B). JAM-A loss of expression
(defined as H-score < 10) correlated with reduced overall survival in
stages II and III CRC [HR: 1.43, 95% CI 1.02–2.02, p= 0.019 (Fig. 1H)] as
well as in stage II only CRC [HR: 1.66, 95% CI 0.90–3.04, p= 0.037
(Fig. 1I)] in the Swiss cohort. These findings were further confirmed in
492 patients in three independent cohorts of stage II colon cancer
[GSE40966 [19] (n= 261); GSE14333 [20] (n= 63); TCGA [21] (n=
168)] and, taken together, suggest that JAM-A downregulation has a
negative prognostic role in early CRC (Supplementary Fig. S2C–E).
Loss of JAM-A increases the proliferative, migratory and
metastatic capacity of CRC
Previous lines of evidence suggest that JAM-A modulation could
affect cell motility in breast and gastric cancers [2, 3, 9, 22–24]. In
order to investigate whether loss of JAM-A influences cell motility
and migration in CRC, we silenced JAM-A in the Caco-2 CRC cell
line using a conditional doxycycline-inducible lentiviral JAM-A
shRNA silencing construct. Caco-2 cells were chosen as they grow
as a 2D monolayer, express relatively high JAM-A mRNA and
protein levels (Supplementary Fig. S3A, B) and have been used
previously to study JAM-A physiopathology [25]. Conditional JAM-
A knockdown caused JAM-A downregulation (Fig. 2A and
Supplementary Fig. S3C), promoted a significant increase in
filopodia formation (p: 0.02) (Fig. 2B) and increased motility by
more than 70% after 120 h [(p < 0.001) Fig. 2C]. Confirming these
data, re-expression of JAM-A by retroviral infection in RKO cells
that lack JAM-A due to promoter methylation (Supplementary Fig.
S3A, B, D, E) restored JAM-A expression and membranous
localisation (Fig. 2D upper panel), and significantly reduced
migration compared to control JAM-A-negative RKO cells
[37% ± 9% vs 100% ± 0% respectively, (p < 0.001) (Fig. 2D lower
panel)]. Differences in wound healing ability of the two cell lines
were not unexpected and reflected doubling time and migratory
potential of the two models [26].
Downregulation of JAM-A also promoted anchorage-
independent cell growth in both Caco-2 (Fig. 2E) and DLD-1
(Fig. 2F and Supplementary Fig. S3F, G) cells. The growth
promoting effect of JAM-A loss in CRC cells was also confirmed
in a tumour spheroid formation assay using the DLD-1 cells that
retain the capacity to form tight 3D spheroids in ultra-low
attachment plates [14]. Following doxycycline activation,
tumour spheroids volume was significantly enhanced in JAM-
A-silenced (JAM-A-sh) compared to JAM-A-expressing (CTRL)
DLD-1 cells [day 5 JAM-A sh vs CTRL: 205% ± 15% vs 169% ± 14%
(p < 0.001); day 7 JAM-A sh vs CTRL: 360% ± 16% vs 246% ± 15%
(p < 0.001); (Fig. 2G)].
Next, we assessed the effect of JAM-A downregulation on
in vivo tumorigenicity. Luciferase-positive Caco-2 cells expressing
JAM-A or control shRNA constructs were implanted in the flank of
nude mice (n= 4 per group) (Supplementary Fig. S4A) and tumour
growth was monitored over a period of 9 weeks using a calliper
(Fig. 3A) and luminescence (Fig. 3B). While the tumorigenic
potential of Caco-2 shRNA CTRL cells was limited, knockdown of
JAM-A significantly increased their ability to form tumours in vivo
(Fig. 3A–C). JAM-A knockdown was associated with a significant
increase in the proliferation marker Ki67 in Caco-2 tumours
(Fig. 3D, E). In order to test whether JAM-A dysregulation also
influenced the metastatic potential of CRC cells, we performed tail
vein injections of DLD-1 cells expressing the JAM-A or control
shRNA constructs and monitored their ability to colonise the lungs
over a period of 12 weeks (Fig. 3F and Supplementary Fig. S4B).
Tail vein injections were conducted using the DLD-1 line instead
of Caco-2, given the latter lack metastatic potential. In vivo
imaging, magnetic resonance and macroscopic examination
(Fig. 3F–I and Supplementary Fig. S4C) confirmed that JAM-A
knockdown promoted the formation of metastatic foci in the
lungs. Histology (Fig. 3H) revealed that JAM-A knockdown was
associated with an increase in the absolute number of lung
metastatic foci, an increase in the total volume of the lung
metastatic burden (Fig. 3I) and increased proliferation in meta-
static deposits (Fig. 3J, K).
Loss of JAM-A orchestrates the activation of pro-survival and
pro-migratory signalling pathways in CRC
Available literature suggests that JAM-A controls cell migration,
proliferation and mitosis through the MAPK/ERK and PI3K/AKT
pathways [6, 27, 28]. In order to assess the contribution of JAM-A
loss on CRC intracellular signalling, we tested changes in phospho-
kinases using a human proteome profiler following conditional JAM-A
silencing in Caco-2 (Supplementary Fig. S3C and Fig. 4A) and DLD-1
cells (Supplementary Fig. 3F and Supplementary Fig. S5A). Out of 43
evaluated phosphoproteins, JAM-A silencing was associated with the
deregulation of 11 targets in Caco-2 cells (Fig. 4A), and 9 in DLD-1 cells
(Supplementary Fig. S5A). In line with previously reported data
[6, 27, 28], both ERK1/2 (T202/Y204, T185/Y187) and AKT 1/2/3 (S473)
phosphorylation increased by 2.5- and 1.5-fold in Caco-2 and DLD-1,
respectively, confirming that JAM-A loss is associated with activation
of these two signalling cascades in CRC. A significant increase in ERK
and AKT phosphorylation following JAM-A knockdown in Caco-2 cells
was further confirmed by cell signalling multiplex luminometric assays
(Fig. 4B, C), and by western blotting (Fig. 4D).
Next, we investigated whether PDK1 and mTOR, the two main
kinases phosphorylating AKT [29, 30], are involved in the AKT
pathway activation in the context of JAM-A downregulation. We
starved doxycycline-induced Caco-2 JAM-A-sh cells overnight and
subsequently stimulated the cells with insulin, in the absence
and presence of either a PDK1 or an mTOR kinase inhibitor
(Supplementary Fig. S5B).
Insulin stimulation of the Caco-2 JAM-A-sh cells led to increased
AKT phosphorylation in both activating sites. Insulin stimulation
failed to induce upregulation of pAKT-Ser476 in the presence of
the mTOR kinase inhibitor, suggesting that mTOR is indeed the
kinase responsible for the phosphorylation of AKT-Ser476 even in
the context of low JAM-A expression. Similarly, insulin stimulation
failed to induce upregulation of pAKT-Thr308 in the presence of
the PDK1 inhibitor, suggesting that PDK1 mediates phosphoryla-
tion of AKT-Thr308 even in the context of low JAM-A expression.
Interestingly, whereas the PDK1 inhibitor selectively prevented
insulin-mediated upregulation of pAKT-Thr308, the mTOR
kinase inhibitor prevented insulin-mediated phosphorylation of
both Ser473 and Thr308 sites. A possible explanation for
this observation can be that in the Caco-2 JAM-A-sh cells, the
phosphorylation of AKT in the Ser473 and Thr308 sites is
interdependent, with phosphorylation at the Ser473 site being a
pre-requisite for the phosphorylation at the Thr308 site to occur. A
similar role for mTOR and PDK1 with regards to AKT activation was
also confirmed in the JAM-A-expressing doxycycline-induced
Caco-2 CTRL cells (Supplementary Fig. S5B). Overall, our observa-
tions suggest that JAM-A modulation does not affect the kinases
that directly regulate AKT activation per se; instead, the increased
AKT activation observed in the context of low JAM-A may be
attributed to other biological processes such as elevated levels of
activity of mTORC2 and PDK1 or increased spatial proximity of the
aforementioned kinases to AKT.
Given the significant increase in the migratory potential
observed following JAM-A silencing in our models and prompted
by the physiological role of the JAM-A/RAP2c/ROCK1 signalling
axis in epithelial barrier function [31–34], we also tested whether
loss of JAM-A may affect motility of CRC cells through the ROCK
kinase pathway. Supporting this hypothesis, western blotting
A. Lampis et al.
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Fig. 2 JAM-A downregulation promotes proliferation and migration in CRC. A Immunofluorescence staining for JAM-A in Caco-2 cells
stably infected with TRIPZ CTRL and TRIPZ JAM-A-sh lentiviral vectors; scale bars 20 μm. B Phalloidin staining showing enhanced filopodia
formation in Caco-2 cells upon JAM-A downregulation (top) and data quantitation (bottom). Scale bar 50 μm. C Scratch wound healing
assay using the Caco-2 TRIPZ CTRL and TRIPZ JAM-A-sh clones; quantification data are expressed as average ± SD of three independent
experiments (t-test, two-sided ***p < 0.001); scale bar 400 μm. D Upper panel: immunofluorescence for RKO cells stably infected with a
JAM-A-overexpressing (+pBABE-JAM-A) or control (CTRL) retroviral vector; scale bars 20 μm. Lower panel: representative images
and quantification of scratch wound healing assay using the CTRL and JAM-A overexpressing RKO clones (t-test two-sided, ***p < 0.001);
scale bars 400 μm. JAM-A silencing (TRIPZ JAM-A sh) promotes anchorage-independent growth of Caco-2 (E) and DLD-1 (F) cells in soft
agar; scale bars 200 μm. G Three-dimensional tumour spheroid formation growth assay upon JAM-A silencing in DLD-1 cells (CTRL n= 10,
JAM-A sh n= 10); scale bars 300 μm. Data are expressed as average ± SD of three independent experiments (t-test two-sided, *p < 0.05,
***p < 0.001).
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Fig. 3 JAM-A downregulation promotes CRC cell growth and metastasis in vivo. Growth of subcutaneous Caco-2 tumours was measured by
calliper (A) and by in vivo imaging using radiance as endpoint (t-test, two-sided *p < 0.05, **p < 0.01, ***p < 0.001) (B). C Representative
examples of explanted tumours and matching in vivo imaging pictures for each of the Caco-2-2 TRIPZ CTRL and TRIPZ JAM-A sh study groups.
D Representative histology (H&E) and immunohistochemistry for JAM-A and Ki67 along with scoring (E) in Caco-2 TRIPZ CTRL and TRIPZ JAM-
A sh tumour explants; scale bars 100 μm. F Lung colonisation following tail vein injections of the TRIPZ JAM-A sh and TRIPZ CTRL DLD-1 clones
was monitored over time using in vivo imaging. G Representative magnetic resonance imaging and lung anatomy 12 weeks post tail vein
injection of the TRIPZ JAM-A sh and TRIPZ CTRL DLD-1 clones showing effective metastatic deposit formation. H Representative histology
(H&E) of lung metastatic sites in mice injected with the TRIPZ JAM-A sh and TRIPZ CTRL DLD-1 clones. I Absolute number, total volume of
metastatic burden and size of individual metastases in mice injected with the TRIPZ JAM-A sh (n= 4) and TRIPZ CTRL DLD-1 clones (n= 4).
J Representative histology (H&E) and immunohistochemistry for JAM-A and Ki67 along with scoring (K) in DLD-1 TRIPZ CTRL and TRIPZ JAM-A
sh lung metastases; scale bars 100 μm.
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Fig. 4 JAM-A silencing activates multiple downstream signalling pathways. A Human phospho-kinase array in TRIPZ JAM-A sh and TRIPZ
CTRL Caco-2 clones. JAM-A silencing was associated with a significant increase in phosphorylation of the indicated proteins. Blots circled in
red on the top left corner represent loading controls proteins. TRIPZ JAM-A sh and TRIPZ CTRL Caco-2 clones were subjected to Luminex assay
for phosphoproteins involved in the MAPK/SAPK (B) and Akt/mTOR (C) pathways. Western blot analysis of the TRIPZ JAM-A sh and TRIPZ CTRL
Caco-2 clones showing the effect of JAM-A silencing on the ERK and AKT (D) and the ROCK1/pMLC (E) signalling pathway. F Quantitation of
blots in D and E (three biological replicates). G Fold change in common proteins deregulated following JAM-A silencing in 2D (Caco-2) and 3D
(R-008 PDO) cellular systems identified with Human Protein 660 plex array (t-test, two-sided p value < 0.05). H Fold change in common genes
deregulated following JAM-A silencing in 2D (Caco-2) and 3D (R-008 PDO) cellular systems identified with nCounter NanoString (t-test, two-
sided p value < 0.05). I Representative histology (H&E) and immunohistochemistry (with total H-scores) for ROCK1, pERK and BMP7 in Caco-2
TRIPZ CTRL and TRIPZ JAM-A sh subcutaneous tumour explants; scale bars 100 μm.
A. Lampis et al.
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analysis showed that upon JAM-A silencing, RAP2c GTP bound
form decreased and this resulted in increased levels in ROCK1 and
non-muscle myosin 2 (pMLC) phosphorylation (Fig. 4E, F).
In order to further investigate gene and protein expression changes
induced by loss of JAM-A, we employed large-scale functional
approaches using Caco-2 monolayers grown in 2D, and PDOs
established from CRC liver metastases growing in 3D (Fig. 1D and
Supplementary 2A). To this end, we interrogated the Caco-2 line and
the R-008 PDO (Supplementary Fig. S5C) expressing either the JAM-A
or control shRNA constructs using a quantitative multiplexed
fluorescent array measuring 660 cytokines. JAM-A downregulation
was associated with the deregulation of 207 cytokines (11
upregulated and 196 downregulated) in the Caco-2 cells (Supple-
mentary Table S1) and with the deregulation of 53 cytokines (23
upregulated and 30 downregulated) in the R-008 PDO line
(Supplementary Table S2). 18 cytokines were commonly deregulated
following JAM-A silencing in both models, with 14 of them showing a
concordant up- or downregulation pattern following JAM-A inactiva-
tion in both cellular systems (Fig. 4G).
We then analysed the gene-expression profile of the same
Caco-2 and R-008 PDO cells expressing either the JAM-A or control
shRNA constructs using the NanoString pan-cancer pathway
panel: Among the 40 genes significantly deregulated in Caco-2
monolayers, 2 (one upregulated and one downregulated) were
dysregulated by more than 2log fold change (Supplementary
Tables S3 and 4 and Supplementary Fig. S5D). Among the genes
deregulated due to JAM-A inactivation in JAM-A sh 3D organoids,
23 were overexpressed and 24 were downregulated by more than
2log fold change (Supplementary Table S5). Overall, 17 genes
were significantly dysregulated both in 2D and 3D with 7 genes
showing concordant changes and ten with opposite (Fig. 4H).
Both cytokine and gene-expression analyses showed that bone
morphogenetic protein 7 (BMP7), a protein involved in the fine-
tuning of the Wnt pathway [35] and a TGFβ1 [36] antagonist, was
consistently downregulated following silencing of JAM-A. In
agreement with this, analysis of the Caco-2 tumour explants
described in Fig. 3A–E confirmed that the silencing of JAM-A also
resulted in BMP7 downregulation in vivo (Fig. 4I).
In summary, JAM-A silencing resulted in the activation of pro-
survival (AKT, ERK) and pro-migratory (ROCK1) signalling path-
ways, and may potentiate TGFβ signalling by downregulating the
TGFβ1 antagonist BMP7.
Elevated levels of MIR21 negatively regulate JAM-A mRNA
expression in CRC
Experiments in animal models have shown that JAM-A down-
modulation follows within 48 h of Apc inactivation in GEMMs [10],
suggesting that non-genetic mechanisms may underpin the loss of
adhesion molecules in CRC progression. Contrary to the epigenetic
regulation of JAM-A expression observed in the RKO CRC cells
(Supplementary Fig. S3A, B, D, E), analysis of 50 cases of sporadic CRC
did not detect JAM-A promoter methylation (data not shown),
suggesting that the reduction in JAM-A expression observed in CRC is
not due to epigenetic silencing of the JAM-A promoter.
MicroRNAs (MiRNAs) are frequently upregulated in CRC and
contribute to disease progression through the post-transcriptional
and translational regulation of various mRNA targets [37]. While
exploring whether the reduction in JAM-A expression observed in
CRC might be due to MiRNA-mediated silencing, we identified a
putative binding site for MIR21, one of the most significantly
upregulated MiRNAs in CRC [38], in the JAM-A 3′-untraslated
region (UTR) (Fig. 5A). To investigate a potential role for MIR21 in
the regulation of JAM-A expression, we looked at endogenous
JAM-A protein levels in a DLD-1 MIR21 isogenic system [39];
consistent with the notion that MIR21 negatively regulates JAM-A
expression, we observed higher levels of endogenous JAM-A
protein in the DLD-1 MIR21KO cells (Fig. 5B). Interestingly,
endogenous JAM-A mRNA levels were higher in the DLD-1
MIR21wt cells, suggesting that the MIR21-mediated regulation of
JAM-A is not due to degradation of the JAM-A mRNA but instead
due to its translational inhibition (Fig. 5B).
To confirm these observations, we silenced and overexpressed
MIR21 in DLD-1 MIR21wt and DLD-1 MIR21KO isogenic cells,
respectively. Silencing of MIR21 in DLD-1 MIR21wt cells increased
JAM-A protein levels (Fig. 5C), while re-expression of MIR21 in
DLD-1 MIR21KO cells decreased JAM-A protein levels (Fig. 5D),
indicating that the translation of the JAM-A mRNA transcript is
regulated by MIR21. A reduction in the JAM-A protein levels
following exogenous MIR21 overexpression was also observed in
HEK-293T cells (Supplementary Fig. S6A) that express very low
levels of endogenous MiRNA [40]. Furthermore, transfection of
RKO cells that lack expression of endogenous JAM-A (Supple-
mentary Fig. S3D) with MC plasmids encoding the JAM-A coding
sequence either under the control of the wt JAM-A 3′-UTR or
under the control of an engineered JAM-A 3′-UTR from which the
MIR21 binding site has been deleted (Fig. 5E cartoon), revealed
that the JAM-A 3′-UTR lacking the MIR21 binding site was more
effective in driving JAM-A protein expression (Fig. 5E). Support-
ing the MIR21-mediated regulation of JAM-A mRNA translation
observed in CRC cell lines, overexpression of MIR21 in a
metastatic CRC PDO line (Supplementary Fig. S6B) also resulted
in reduced JAM-A protein levels both ex vivo and in vivo and,
despite the small sample size (n= 2 per condition), was
associated with increased tumour proliferation (Fig. 5F, G and
Supplementary Fig. S6C).
The direct binding of MIR21 to the JAM-A 3′-UTR was confirmed
using luciferase reporter assays in the DLD-1 MIR21 isogenic cell
system. Compared to the levels observed in the DLD-1 MIR21KO,
luciferase activity was suppressed by endogenous MIR21 in the DLD-1
MIR21wt cells when the luciferase gene was under the regulation of
the wt JAM-A 3′UTR; mutagenesis of MIR21 binding site restored
luciferase activity (Fig. 5H). Likewise, exogenous MIR21 up- and
downregulation reduced and increased luciferase activity in the DLD-
1 MIR21KO and MIR21wt cells, respectively; these effects were
abrogated when an engineered version of the JAM-A 3′-UTR lacking
the MIR21 binding site was used (Fig. 5I). Taken together these
observations suggest a direct regulation of JAM-A mRNA translation
by MIR21 binding to the JAM-A 3′-UTR.
Overexpression of MIR21 has been linked to CRC invasion,
migration and progression [38]. In order to test whether MIR21
overexpression could recapitulate the phenotype observed upon
JAM-A modulation in CRC pre-clinical models (Fig. 2A–G), we
generated Caco-2 and DLD-1 cell lines carrying a conditional
doxycycline-inducible MIR21 construct and confirmed physiologi-
cal expression of MIR21 following induction with doxycycline in
both systems (Supplementary Fig. S6D, E). In agreement with data
observed following JAM-A downregulation in Caco-2 cells (Fig. 2C),
MIR21 upregulation also resulted in a significant increase in
migration of Caco-2 cells over 3 days (Fig. 5J). Given that 3D assays
appear to recapitulate more closely the in vivo cancer physiology
[14, 41], we further validated our findings in a 3D migration assay
using the DLD-1 cell line and confirmed that MIR21 over-
expression induced increased migration also in 3D spheroid
conditions (Fig. 5K).
In order to test whether the effect on cell growth and migration
observed upon MIR21 overexpression in the DLD-1 cells was due
to JAM-A downregulation, we performed rescue experiments
where the suppression of endogenous JAM-A induced by MIR21
overexpression was compensated for by exogenous expression of
the JAM-A transcript under the control of either a wt 3′-UTR or an
engineered 3′-UTR that lacks the MIR21 binding site (Fig. 5E
cartoon). MIR21-overexpressing DLD-1 cells co-expressing the
JAM-A transcript under the control of a wt 3′-UTR proliferated
faster compared to MIR21-overexpressing cells co-expressing the
JAM-A transcript under the control of the mutant 3′-UTR lacking
the MIR21 binding site. These observations were consistent with
A. Lampis et al.
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the idea that deletion of the MIR21 binding site in the 3′-UTR of
JAM-A leads to the abrogation of the MIR21-dependent JAM-A
downmodulation, resulting in impaired tumour growth and cell
migration in 3D. These effects were observed within 5–7 days
from MIR21 overexpression for cell proliferation (Fig. 5L) and as
early as 24 h for cell migration (Fig. 5M).
Finally, given activating feedforward loops involving miRs and
their downstream effectors have been previously described [42],
we investigated whether AKT modulation might affect MIR21 and
JAM-A expression. However, both insulin and the allosteric pan-
AKT inhibitor MK-2206 failed to induce significant or persistent
changes in MIR21 expression or JAM-A protein levels in
doxycycline-induced JAM-Ash or CTRL Caco-2 cells, making the
presence of an activating feedback loop unlikely (Supplementary
Fig. S6F, G).
DISCUSSION
Here, we provide evidence for a functional link between
overexpression of the oncogenic MIR21, a hallmark of CRC,
A. Lampis et al.
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reduced expression of the adhesion molecule JAM-A and
activation of several oncogenic pathways promoting proliferation,
cell migration and disease progression.
We observe that JAM-A downregulation is frequent in CRC and
correlates with poor prognosis, particularly in patients with stage II
CRC for whom the decision to offer adjuvant treatment is often
controversial [43]. From a therapeutic angle, these observations are of
particular importance, because they suggest that, contrary to other
diseases such as breast cancer and multiple myeloma where JAM-A
inhibitors may represent potential therapeutic strategies [7, 44], JAM-
A suppression in CRC may have a detrimental effect on patient
outcomes. Indeed, JAM-A dysregulation has been observed in
multiple tumour types; however, while in breast, lung and head
and neck cancers [2–6], JAM-A overexpression enhances proliferation
and promotes resistance to targeted therapies [27], in gastrointestinal
cancers including gastric and pancreatic neoplasms [8, 9], as well as in
thyroid tumours [45], it is JAM-A downregulation that is associated
with cancer acceleration and worse prognosis.
In this regard, our study fills in an important gap, because,
although the contribution of JAM-A loss in intestinal inflammation
is well characterised [46], little is known about its role on CRC
tumorigenesis. So far, hints on the involvement of JAM-A in the
neoplastic transformation of intestinal cells come from GEMMs, in
which conditional inactivation of Apc in the large intestine results
in rapid JAM-A downregulation, loss of barrier function, penetra-
tion of microbiota and activation of an inflammatory response by
myeloid cells in the cancer microenvironment [10].
Our data suggest that JAM-A loss has a cell-autonomous, pro-
tumorigenic effect of CRC progression that goes beyond the
mere permissive effect of eliciting an inflammatory response
due to impaired intestinal epithelium barrier function. Indeed,
we demonstrate that JAM-A downmodulation retains the ability
to promote the CRC phenotype even in absence of
microenvironment-related stimuli, an observation in line with
data suggesting that JAM-A downregulation in normal fibro-
blasts accelerates cell proliferation and migration via activation
of the MAPK pathway [47].
JAM-A downmodulation follows within hours from Apc loss in
CRC animal models [10]. In our three cohorts of human CRC,
histological analysis of JAM-A shows reduced or patchy
expression in ~40% of cases, with a minority of patients
presenting complete JAM-A loss. Altogether, these data suggest
that abnormalities in the fine-tuning of JAM-A expression at the
post-transcriptional or post-translational level may be respon-
sible for the observed JAM-A downregulation in CRC, rather than
genetic or epigenetic events. This hypothesis is supported by
the observation that JAM-A promoter methylation was not
detected in any of the patients we tested. On the contrary, our
data suggest that MIR21 upregulation may be one of the drivers
of JAM-A silencing in CRC. We have shown that miR dysregula-
tion plays a critical role in CRC initiation, progression and
resistance to anticancer treatments [37, 38, 42]. Here, we
demonstrate that JAM-A downregulation is caused, at least in
part, by MIR21 overexpression, and that JAM-A rescue signifi-
cantly abrogates the pro-proliferative and pro-migratory effects
of MIR21. Although we provide robust evidence to support a
direct regulatory effect of MIR21 on JAM-A expression, we
acknowledge that other mechanisms may come into play in
controlling adhesion molecules. JAM-A phosphorylation at
tyrosine residue Y280 has been reported as a cytokine-induced
and SRC-mediated mechanism for barrier function inactivation
in human and animal models of colitis [48]. Given MIR21 is
involved in the synthesis of numerous inflammatory cytokines
such as IL-23 and IL-17A [49] in the colon mucosa, it is possible
that a positive feedback loop involving MIR21 overexpression,
synthesis of pro-inflammatory factors and activation of onco-
genic pathways may also contribute to JAM-A inactivation and
the downstream consequences on barrier function and cancer
promotion.
The pleiotropic function that JAM-A dysregulation has in CRC
compared to other cancer types may relate to tissue-specific
differences in transcriptome and miRNAome [50] as well as the
intracellular signalling pathways and downstream genes affected by
JAM-A downmodulation. For instance, JAM-A deregulation has been
shown to activate NFkB [51], MAPK [47, 52] and PI3K [28, 53] signalling
cascades in a tissue- and ligand-specific manner, an observation
confirmed by our pre-clinical models where loss of JAM-A induced
activation of the ERK and AKT pathways.
Although we did not explore any causal relation between β-catenin
activation, MIR21 overexpression and JAM-A downregulation, it is
noteworthy that, similarly to JAM-A loss [52], MIR21 is also able to
promote pSer552 phosphorylation of β-catenin and its nuclear
translocation in APC mutant colon cancer cells [54]. The β-catenin/
TCF activated pathway is known to enhance expression of signal
transducer and activator of transcription 3 (STAT3) [55], whose
consensus sequence binding sites are present upstream of the pri-
MIR21 transcription starting site [56]. Taken together, these observa-
tions suggest the presence of a potential feedforward loop, whereby
loss of APC and activation of β-catenin may trigger STAT3-mediated
overexpression of MIR21, and subsequent MIR21-dependent down-
regulation of JAM-A; this hypothesis is supported by the fact that two
of the CRC cell lines with the highest MIR21 expression (HCT116 and
Caco-2) have activating mutations in β-catenin.
A significant downregulation of BMP7 was consistently observed
in our models following JAM-A signalling. BMPs attenuate Wnt
pathway activity [35, 57] by buffering the nuclear accumulation of
β-catenin via PTEN-dependent inhibition of AKT signalling. BMPs are
generally downregulated in CRC [58, 59] and BMP signalling is
known to counteract TGFβ signalling [57], a previously reported
negative regulator of JAM-A [60]. Taken together, these observations
suggest that the suppression of BMP7 signalling due to loss of JAM-
A may also increase β-catenin activity, thereby further promoting
MIR21 transcription, sustaining JAM-A downregulation and promot-
ing CRC progression.
Fig. 5 MIR21 regulates expression of JAM-A mRNA. A In silico prediction of a MIR21 binding site in the JAM-A 3′-UTR. Bases highlighted in
red indicate the part deleted by site-directed mutagenesis in the luciferase reporter assays described in H and I. B Endogenous JAM-A mRNA
and protein expression in the DLD-1 MIR21 isogenic cell system. Effects of MIR21 silencing (C) and upregulation (D) on JAM-A expression in
DLD-1 MIR21KO and MIR21wt cells (t-test, two-sided ***p < 0.001). E Re-expression of the JAM-A coding sequence in RKO cells, either under the
control of the wt JAM-A 3′-UTR (JAM-A 3′-UTR WT) or under the control of an engineered JAM-A 3′-UTR lacking the MIR21 binding site (JAM-A
3′-UTR Del- MIR21). F PDOs with high endogenous JAM-A expression were infected with doxycycline-inducible pre-MIR21 (TRIPZ MIR21) or
control (TRIPZ CTRL) lentiviral vectors; scale bars 50 μm. G Representative histology (H&E), MIR21 expression (in situ hybridisation) and JAM-A
and Ki67 expression (IHC) in tumours at end of experiment; scale bars 100 μm. Luciferase reporter assays assessing the impact of endogenous
(H) or exogenous (I) (pre-MIR21; LNA anti-MIR21) MIR21 on the wt or mutant (MIR21 deleted) JAM-A 3′-UTR (t-test, two-sided ***p < 0.001).
Scratch wound healing assay (J) and three-dimensional migration of spheroids through gelatine (K) in MIR21-overexpressing cells (TRIPZ
MIR21) compared to controls (t-test, two-sided *p < 0.05, **p < 0.01, ***p < 0.001). Rescue experiments showing 3D tumour growth (L) and 3D
migration (M) (t-test, two-sided *p < 0.05, **p < 0.01, ***p < 0.001) in MIR21-overexpressing DLD-1 spheroids (n= 12 each group) transfected
with minicircle plasmids containing the JAM-A coding sequence under the control of the intact (wt) JAM-A 3′-UTR or under control of JAM-A
3′-UTR lacking the MIR21 binding site; scale bars 300 μm.
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In summary, our data provide novel insights on the cell-intrinsic
effect of JAM-A downregulation in colonic tumorigenesis (Fig. 6),
and suggest that, beside their well-established role in epithelial
barrier function, adhesion molecules also regulate the proliferative
and migratory potential of CRC cells by fine-tuning multiple pro-
oncogenic signalling cascades.
DATA AVAILABILITY
NanoString nCounter data have been deposited in the NCBI Gene Expression
Omnibus (GEO), with accession code GSE149658.
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